UA79537C2 - Indazolamides possessing analgesic activity - Google Patents

Indazolamides possessing analgesic activity Download PDF

Info

Publication number: UA79537C2
Authority: UA; Ukraine
Prior art keywords: product; methyl; indazole; piperidyl; acid
Prior art date: 2003-02-18

Application number

UAA200508163A

Other languages

English (en)

Ukrainian (uk)

Inventor

Maria Alessandra Alici

Nicola Cazzolla

Angelo Guglielmotti

Guido Furlotti

Guiseppe Luna

Lorenzo Polenzani

Original Assignee

Acraf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-18

Filing date

2004-01-26

Publication date

2007-06-25

2004-01-26 Application filed by Acraf filed Critical Acraf

2007-06-25 Publication of UA79537C2 publication Critical patent/UA79537C2/uk

Links

DITBWPUMEUDVLU-UHFFFAOYSA-N 1h-indazole-3-carboxamide Chemical class C1=CC=C2C(C(=O)N)=NNC2=C1 DITBWPUMEUDVLU-UHFFFAOYSA-N 0.000 title abstract description 9
230000000202 analgesic effect Effects 0.000 title description 6
239000002253 acid Substances 0.000 abstract description 18
238000000034 method Methods 0.000 abstract description 18
150000003839 salts Chemical class 0.000 abstract description 9
239000008194 pharmaceutical composition Substances 0.000 abstract description 7
238000002360 preparation method Methods 0.000 abstract description 5
239000000047 product Substances 0.000 description 52
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
150000001875 compounds Chemical class 0.000 description 28
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
-1 aminosulfonylmethyl Chemical group 0.000 description 15
238000000921 elemental analysis Methods 0.000 description 15
235000019441 ethanol Nutrition 0.000 description 15
238000001704 evaporation Methods 0.000 description 15
239000000203 mixture Substances 0.000 description 15
229940093499 ethyl acetate Drugs 0.000 description 14
235000019439 ethyl acetate Nutrition 0.000 description 14
230000008020 evaporation Effects 0.000 description 14
208000002193 Pain Diseases 0.000 description 13
125000005936 piperidyl group Chemical group 0.000 description 13
239000000725 suspension Substances 0.000 description 12
238000002844 melting Methods 0.000 description 11
230000008018 melting Effects 0.000 description 11
239000011541 reaction mixture Substances 0.000 description 11
239000002904 solvent Substances 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
238000005481 NMR spectroscopy Methods 0.000 description 10
241000700159 Rattus Species 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
239000002244 precipitate Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
238000011282 treatment Methods 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
208000004454 Hyperalgesia Diseases 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000000354 decomposition reaction Methods 0.000 description 8
238000003818 flash chromatography Methods 0.000 description 8
230000036407 pain Effects 0.000 description 8
238000005160 1H NMR spectroscopy Methods 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000012074 organic phase Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 5
208000000094 Chronic Pain Diseases 0.000 description 5
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
208000000114 Pain Threshold Diseases 0.000 description 5
DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 5
125000005843 halogen group Chemical group 0.000 description 5
208000004296 neuralgia Diseases 0.000 description 5
230000037040 pain threshold Effects 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
239000013049 sediment Substances 0.000 description 5
102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
208000021722 neuropathic pain Diseases 0.000 description 4
230000004044 response Effects 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
208000032131 Diabetic Neuropathies Diseases 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
208000035154 Hyperesthesia Diseases 0.000 description 3
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000000370 acceptor Substances 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
150000003857 carboxamides Chemical class 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
230000003412 degenerative effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
230000003902 lesion Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000003141 lower extremity Anatomy 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
230000007170 pathology Effects 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
238000010992 reflux Methods 0.000 description 3
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
229960001052 streptozocin Drugs 0.000 description 3
239000000126 substance Substances 0.000 description 3
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
208000001640 Fibromyalgia Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000003282 alkyl amino group Chemical group 0.000 description 2
125000005037 alkyl phenyl group Chemical group 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
206010053552 allodynia Diseases 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
230000003040 nociceptive effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
238000000746 purification Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
238000005303 weighing Methods 0.000 description 2
OVVDFORZEGKEJM-UHFFFAOYSA-N 1-methylindazole-3-carboxylic acid Chemical compound C1=CC=C2N(C)N=C(C(O)=O)C2=C1 OVVDFORZEGKEJM-UHFFFAOYSA-N 0.000 description 1
BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 description 1
NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
WEGHDQAIAVOWLZ-UHFFFAOYSA-N 2-phenylacetamide;dihydrochloride Chemical compound Cl.Cl.NC(=O)CC1=CC=CC=C1 WEGHDQAIAVOWLZ-UHFFFAOYSA-N 0.000 description 1
DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
QRTAIBBOZNHRMI-UHFFFAOYSA-N 5-methyl-1h-indazole-3-carboxylic acid Chemical compound CC1=CC=C2NN=C(C(O)=O)C2=C1 QRTAIBBOZNHRMI-UHFFFAOYSA-N 0.000 description 1
241000234282 Allium Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
229910014248 MzO2 Inorganic materials 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000008765 Sciatica Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000001618 algogenic effect Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
150000003935 benzaldehydes Chemical class 0.000 description 1
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000011928 denatured alcohol Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
239000003777 experimental drug Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000005469 granulation Methods 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
150000002473 indoazoles Chemical class 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000000771 oncological effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
WDQHNGWWTZNMPN-UHFFFAOYSA-N oxalic acid;1-propan-2-ylindazole-3-carboxamide Chemical compound OC(=O)C(O)=O.C1=CC=C2N(C(C)C)N=C(C(N)=O)C2=C1 WDQHNGWWTZNMPN-UHFFFAOYSA-N 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 1
LTEKQAPRXFBRNN-UHFFFAOYSA-N piperidin-4-ylmethanamine Chemical compound NCC1CCNCC1 LTEKQAPRXFBRNN-UHFFFAOYSA-N 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
ZIKJCAPMXXTMDD-UHFFFAOYSA-M sodium;2-(1-hydroxycyclohexyl)butanoate Chemical compound [Na+].CCC(C([O-])=O)C1(O)CCCCC1 ZIKJCAPMXXTMDD-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
235000014347 soups Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
229950001870 spizofurone Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000008733 trauma Effects 0.000 description 1
210000003901 trigeminal nerve Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

UAA200508163A 2003-02-18 2004-01-26 Indazolamides possessing analgesic activity UA79537C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT000287A ITMI20030287A1 (it)	2003-02-18	2003-02-18	Indazolammidi dotate di attivita' analgesica metodo, per
PCT/EP2004/000647 WO2004074275A1 (en)	2003-02-18	2004-01-26	Indazolamides with analgesic activity

Publications (1)

Publication Number	Publication Date
UA79537C2 true UA79537C2 (en)	2007-06-25

Family

ID=32894157

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200508163A UA79537C2 (en)	2003-02-18	2004-01-26	Indazolamides possessing analgesic activity

Country Status (22)

Country	Link
US (2)	US7632849B2 (de)
EP (1)	EP1594859B1 (de)
JP (1)	JP4724651B2 (de)
KR (1)	KR101108222B1 (de)
CN (2)	CN101139341B (de)
AR (1)	AR043186A1 (de)
AT (1)	ATE471934T1 (de)
AU (1)	AU2004213104B2 (de)
CA (1)	CA2511984C (de)
DE (1)	DE602004027792D1 (de)
DK (1)	DK1594859T3 (de)
EA (1)	EA009077B1 (de)
ES (1)	ES2345983T3 (de)
GE (1)	GEP20074075B (de)
IL (1)	IL169285A (de)
IT (1)	ITMI20030287A1 (de)
MX (1)	MXPA05008730A (de)
PL (1)	PL215870B1 (de)
PT (1)	PT1594859E (de)
SI (1)	SI1594859T1 (de)
UA (1)	UA79537C2 (de)
WO (1)	WO2004074275A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20031468A1 (it) *	2003-07-18	2005-01-19	Acraf	Farmaco ativo nel dolore neuropatico
AU2005254800B2 (en)	2004-06-15	2010-12-09	Pfizer Inc.	Benzimidazolone carboxylic acid derivatives
NZ587799A (en) *	2008-03-25	2012-06-29	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
US8815892B2 (en)	2008-03-25	2014-08-26	Affectis Pharmaceuticals Ag	P2X7R antagonists and their use
ES2380908T3 (es) *	2009-04-14	2012-05-21	Affectis Pharmaceuticals Ag	Antagonistas de p2x7r novedosos y su uso
EA026952B1 (ru)	2012-02-21	2017-06-30	Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.	Применение 1h-индазол-3-карбоксамидных соединений в качестве ингибиторов гликогенсинтазы киназы 3-бета
AU2013224302B2 (en)	2012-02-21	2017-03-30	Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.	1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
EP2970177A1 (de)	2013-03-15	2016-01-20	Pfizer Inc.	Indolverbindungen zur ampk-aktivierung
US11472795B2 (en)	2018-05-07	2022-10-18	AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A.	1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
CN109336890B (zh) *	2018-11-17	2020-03-20	重庆文理学院	一种吲唑类衍生物的合成方法及抗肿瘤应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3705175A (en) *	1969-04-01	1972-12-05	Egyt Gyogyszervegyeszeti Gyar	Indazole-3-carboxylic amides
IL117438A (en) *	1995-03-16	2001-12-23	Lilly Co Eli	Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
US5654320A (en) *	1995-03-16	1997-08-05	Eli Lilly And Company	Indazolecarboxamides
KR19990022096A (ko)	1995-05-31	1999-03-25	쇼다 오사무	모노시클릭 아미노기를 갖는 인다졸 유도체
CN1093801C (zh) *	1995-11-08	2002-11-06	东丽株式会社	直接成像型无水平版印刷版原版
TR199900321T2 (xx)	1996-08-16	1999-04-21	Smithkline Beecham P.L.C.	N-(1-nbutil - 4 - piperidil)metil) -3,4-dihidro -2H- (1,3) oksazino (3.2A) indol-10- Karboksamit haz�rlama prosesi ve prosesteki tuzlar ve ara �r�nler.
IT1291569B1 (it)	1997-04-15	1999-01-11	Angelini Ricerche Spa	Indazolammidi come agenti serotoninergici
US6339087B1 (en) *	1997-08-18	2002-01-15	Syntex (U.S.A.) Llc	Cyclic amine derivatives-CCR-3 receptor antagonists
US6069152A (en) *	1997-10-07	2000-05-30	Eli Lilly And Company	5-HT4 agonists and antagonists
US6407103B2 (en) *	1998-04-21	2002-06-18	Bristol-Myers Squibb Pharma Company	Indeno [1,2-c] pyrazol-4-ones and their uses
CN1297442A (zh) *	1998-04-21	2001-05-30	杜邦药品公司	用作抗癌剂和抗增殖剂的5－氨基茚并[1,2－c]吡唑－4－酮类化合物

2003
- 2003-02-18 IT IT000287A patent/ITMI20030287A1/it unknown
2004
- 2004-01-26 PL PL377236A patent/PL215870B1/pl unknown
- 2004-01-26 MX MXPA05008730A patent/MXPA05008730A/es active IP Right Grant
- 2004-01-26 CN CN2007101801011A patent/CN101139341B/zh not_active Expired - Fee Related
- 2004-01-26 UA UAA200508163A patent/UA79537C2/uk unknown
- 2004-01-26 SI SI200431488T patent/SI1594859T1/sl unknown
- 2004-01-26 DK DK04705070.3T patent/DK1594859T3/da active
- 2004-01-26 AT AT04705070T patent/ATE471934T1/de active
- 2004-01-26 AU AU2004213104A patent/AU2004213104B2/en not_active Ceased
- 2004-01-26 ES ES04705070T patent/ES2345983T3/es not_active Expired - Lifetime
- 2004-01-26 PT PT04705070T patent/PT1594859E/pt unknown
- 2004-01-26 JP JP2006501608A patent/JP4724651B2/ja not_active Expired - Fee Related
- 2004-01-26 CN CNB2004800025681A patent/CN100347168C/zh not_active Expired - Fee Related
- 2004-01-26 KR KR1020057014055A patent/KR101108222B1/ko not_active Expired - Fee Related
- 2004-01-26 US US10/541,209 patent/US7632849B2/en not_active Expired - Fee Related
- 2004-01-26 CA CA2511984A patent/CA2511984C/en not_active Expired - Fee Related
- 2004-01-26 GE GEAP20048983A patent/GEP20074075B/en unknown
- 2004-01-26 EA EA200501164A patent/EA009077B1/ru not_active IP Right Cessation
- 2004-01-26 WO PCT/EP2004/000647 patent/WO2004074275A1/en not_active Ceased
- 2004-01-26 DE DE602004027792T patent/DE602004027792D1/de not_active Expired - Lifetime
- 2004-01-26 EP EP04705070A patent/EP1594859B1/de not_active Expired - Lifetime
- 2004-02-16 AR ARP040100467A patent/AR043186A1/es not_active Application Discontinuation
2005
- 2005-06-20 IL IL169285A patent/IL169285A/en not_active IP Right Cessation
2009
- 2009-10-28 US US12/607,463 patent/US8519139B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PL215870B1 (pl)	2014-02-28
AR043186A1 (es)	2005-07-20
EP1594859B1 (de)	2010-06-23
CA2511984C (en)	2011-01-18
KR20050101541A (ko)	2005-10-24
JP2006517932A (ja)	2006-08-03
GEP20074075B (en)	2007-03-26
MXPA05008730A (es)	2005-09-20
ATE471934T1 (de)	2010-07-15
US20060052417A1 (en)	2006-03-09
WO2004074275A1 (en)	2004-09-02
SI1594859T1 (sl)	2010-10-29
KR101108222B1 (ko)	2012-02-08
AU2004213104A1 (en)	2004-09-02
CN1742004A (zh)	2006-03-01
US8519139B2 (en)	2013-08-27
CN101139341B (zh)	2010-12-08
PT1594859E (pt)	2010-07-23
AU2004213104B2 (en)	2010-07-08
US7632849B2 (en)	2009-12-15
DK1594859T3 (da)	2010-10-11
EA200501164A1 (ru)	2005-12-29
DE602004027792D1 (de)	2010-08-05
CN101139341A (zh)	2008-03-12
IL169285A (en)	2012-08-30
PL377236A1 (pl)	2006-01-23
HK1079199A1 (en)	2006-03-31
EP1594859A1 (de)	2005-11-16
EA009077B1 (ru)	2007-10-26
CA2511984A1 (en)	2004-09-02
JP4724651B2 (ja)	2011-07-13
ITMI20030287A1 (it)	2004-08-19
US20100048907A1 (en)	2010-02-25
ES2345983T3 (es)	2010-10-07
CN100347168C (zh)	2007-11-07

Publication	Publication Date	Title
US8519139B2 (en)	2013-08-27	Indazolamides with analgesic activity
DE69918687T2 (de)	2005-07-28	4-Phenylpiperidine zur Behandlung von pruritischen Hauterkrankungen
BRPI0920834B1 (pt)	2020-11-24	processo para preparação de derivados protegidos de l-alanina
JP5138589B2 (ja)	2013-02-06	神経因性疼痛を抑制するピロリジン類縁体及びその製造方法
CA2524498C (en)	2012-01-24	4-(2-furoyl)aminopiperidine compound useful as therapeutic agent for itching
AU2004238449B2 (en)	2010-09-02	Indazole having analgesic activity ,
CN106187898A (zh)	2016-12-07	氨基甲酸酯衍生物及其合成方法和用途
SK162795A3 (en)	1996-09-04	N-substituted azaheterocyclic carboxylic acids and esters thereof, preparation method thereof and pharmaceutical compositions containing them
DE69608699T2 (de)	2000-11-23	Fluorsubstituierte benzoylpropionsaürederivate
TWI799691B (zh)	2023-04-21	具有側鏈烷基與烯基延伸的苯基衍生物及包括有其的藥學組合物
JPH0395143A (ja)	1991-04-19	アミノケトン誘導体
HK1079199B (en)	2010-11-19	Indazolamides with analgesic activity
HK1087705B (en)	2011-06-03	Indazoles having analgesic activity
CZ334695A3 (en)	1996-08-14	N-substituted azaheterocyclic carboxylic acids and esters thereof